Verve Therapeutics Inc Forecast, price target & analysts
Verve Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Verve Therapeutics Inc Classifications & Recommendation:
Verve Therapeutics Inc Price Target
| Target Price | $25.80 |
| Price | $6.20 |
| Potential |
316.13%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Verve Therapeutics Inc 2026 .
The average Verve Therapeutics Inc target price is $25.80.
This is
316.13%
register free of charge
$32.00
416.13%
register free of charge
$18.00
190.32%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend Verve Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Verve Therapeutics Inc stock has an average upside potential 2026 of
316.13%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 11.76 | 22.34 |
| 506.19% | 89.95% | |
| EBITDA Margin | -1,850.94% | -1,046.10% |
| 77.41% | 43.48% | |
| Net Margin | -2,245.55% | -1,011.68% |
| 82.31% | 54.95% |
4 Analysts have issued a sales forecast Verve Therapeutics Inc 2024 . The average Verve Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Verve Therapeutics Inc 2024 . The average Verve Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
1 Analyst has issued a net profit forecast Verve Therapeutics Inc 2024 . The average Verve Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.12 | -2.67 |
| 7.22% | 14.42% | |
| P/E | negative | |
| EV/Sales | 2.94 |
1 Analysts have issued a Verve Therapeutics Inc forecast for earnings per share. The average Verve Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Verve Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Verve Therapeutics Inc...
Current Verve Therapeutics Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity | Locked ➜ Locked | Locked | Nov 06 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 06 2024 |
| RBC Capital | Locked ➜ Locked | Locked | Nov 06 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity: Locked ➜ Locked
|
Nov 06 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 06 2024 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Nov 06 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
